Skip to main content
Journal cover image

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

Publication ,  Conference
Mellinghoff, IK; Wen, PY; Taylor, JW; Maher, EA; Arrillaga-Romany, I; Peters, KB; Le, K; Tai, F; Steelman, L; Cloughesy, TF
Published in: Neuro-Oncology
September 6, 2019

Duke Scholars

Published In

Neuro-Oncology

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

September 6, 2019

Volume

21

Issue

Supplement_3

Start / End Page

iii2 / iii2

Publisher

Oxford University Press (OUP)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mellinghoff, I. K., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga-Romany, I., Peters, K. B., … Cloughesy, T. F. (2019). PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1. In Neuro-Oncology (Vol. 21, pp. iii2–iii2). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noz126.004
Mellinghoff, I. K., P. Y. Wen, J. W. Taylor, E. A. Maher, I. Arrillaga-Romany, K. B. Peters, K. Le, F. Tai, L. Steelman, and T. F. Cloughesy. “PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1.” In Neuro-Oncology, 21:iii2–iii2. Oxford University Press (OUP), 2019. https://doi.org/10.1093/neuonc/noz126.004.
Mellinghoff IK, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, et al. PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1. In: Neuro-Oncology. Oxford University Press (OUP); 2019. p. iii2–iii2.
Mellinghoff, I. K., et al. “PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1.” Neuro-Oncology, vol. 21, no. Supplement_3, Oxford University Press (OUP), 2019, pp. iii2–iii2. Crossref, doi:10.1093/neuonc/noz126.004.
Mellinghoff IK, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Le K, Tai F, Steelman L, Cloughesy TF. PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1. Neuro-Oncology. Oxford University Press (OUP); 2019. p. iii2–iii2.
Journal cover image

Published In

Neuro-Oncology

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

September 6, 2019

Volume

21

Issue

Supplement_3

Start / End Page

iii2 / iii2

Publisher

Oxford University Press (OUP)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences